AHA 2019 The BETonMACE trial evaluating apabetalone did not reduce the primary composite efficacy outcome, nor key secondary outcomes, in T2DM patiens with recent ACS and low HDL-c.
AHA 2019 The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.
AHA 2019 The ORION-10 data showed LDL-c lowering of over 50% with inclisiran, which inhibitors production of PCSK9 through RNA interference, with a safety profile similar to placebo.
Final results from the open-label OSLER-1 study on evolocumab show long-term reduction in LDL-C levels without attenuation of the LDL-lowering effect and consistent safety and tolerability profiles during 5-years.
Long-term follow-up of persons with FH who started statin therapy in childhood shows that progression of cIMT was slowed to the rate seen in unaffected siblings, and CV event risk was reduced.
Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.
Before listing the differences between the AHA/ACC 2018 and ESC/EAS 2019 dyslipidemia guidelines, prof. Ballantyne shares common themes and shared concept across the guidelines.
Starting evolocumab treatment on top of high-intensity statin, in the hospital soon after ACS, safely and effectively lowers LDL-c to below guideline-recommended levels for almost all.
Topline results of ORION-9 and ORION-10 showed durable and potent efficacy and safety of twice-yearly injections of inclisiran in HeFH patients and participants with ASCVD, respectively.
In the FOURIER trial, evolocumab reduced LDL-c by ~60% in patients with established CVD. Prof. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor.
Prof. Kastelein discusses new strategies to target PCSK9, including twice-a-year injections of inclisiran and a new developed oral PCSK9 inhibitor.
ESC 2019 Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.